openPR Logo
Press release

Rheumatoid Arthritis Drug Market Rheumatoid Arthritis Clinical Pipeline Report 2022

07-11-2017 11:14 AM CET | Health & Medicine

Press release from: Kuick Resarch

Rheumatoid Arthritis Drug Market Rheumatoid Arthritis

For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990

Report Table of Contents

Antirheumatoids: Call of Rheumatoid Arthritis
1.1 Prologue towards Rheumatoid Arthritis
1.2 Obtainable Treatment for Rheumatoid Arthritis

Molecular Mechanism of Antirheumatoids
2.1 Purpose of DMARDs in Rheumatoid Arthritis
2.2 Role of Biological Agents in Rheumatoid Arthritis
2.2.1 TNF- Inhibitors
2.2.2 Interleukin -1 and IL-6 Blockers

Classification of Rheumatoid Arthritis Drugs
3.1 Traditional Classification of Rheumatoid Arthritis Drugs
3.2 New Proposed Classification of DMARDs

Synthetic DMARDs as Rheumatoid Arthritis Drug
4.1 Methotrexate (MTX)
4.2 Sulfasalazine (SSZ)
4.3 Leflunomide
4.4 Hydroxychloroquine (HCQ)

Biological Agents as Rheumatoid Arthritis Drug
5.1 Cytokine Inhibitors
5.1.1 Etanercept (Enbrel)
5.1.2 Infliximab (Remicade)
5.1.3 Adalimumab (Humira)
5.1.4 Golimumab (Simponi)
5.1.5 Certolizumab pegol (Cimzia)
5.2 Interleukin 1 and Interleukin 6 Inhibitors
5.2.1 Anakinra (Kineret)
5.2.2 Tocilizumab (RoActerma)
5.3 T-Cell and B-Cell Inhibitors
5.3.1 Abatacept (Orencia)
5.3.2 Rituximab (Mabthera)

Global Prevalence of Rheumatoid Arthritis
6.1 US
6.2 Europe
6.3 Canada
6.4 Asia

Global Tendencies in Use of Antirheumatics
7.1 Trail from Conventional to Biological DMARDs
7.2 Global Trends of Antirheumatic Prescription

Global Market of Rheumatoid Arthritis Drug
8.1 Market Overview of DMARDs
8.2 Market of Biosimilar DMARDs
8.3 Top Leading DMARDs by Revenues (2015 and 2022)
8.3.1 Humira (Adalimumab)
8.3.2 Enbrel (Etanercept)
8.3.3 Remicade
8.3.4 Simponi
8.3.5 Otezla (Celgene)

Global Rheumatoid Arthritis Drug Market Dynamics
9.1 Accelerative Parameters
9.2 Challenges

Global Rheumatoid Arthritis Drug Market Future Prospect

Competitive Landscape
11.1 Abbvie
11.2 Biogen Idec
11.3 Bristol-Myers Squibb
11.4 Celgene
11.5 Celltrion
11.6 JandJ
11.7 MedImmune
11.8 Merck
11.9 Novartis
11.10 Takeda

Download Report: https://www.kuickresearch.com/report-global-rheumatoid-arthritis-drug-market-outlook-2022.php

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
Avanta Business Center 4th Floor,
Statesman House Barakhamba Road,
Connaught Place New Delhi – 110 001, India
+91-11-47067990

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Rheumatoid Arthritis Drug Market Rheumatoid Arthritis Clinical Pipeline Report 2022 here

News-ID: 618511 • Views: 358

More Releases from Kuick Resarch

Global Orphan Drug Rare Disease Market Clinical Trials Forecast 2028
Global Orphan Drugs Clinical Trials Insight Report Highlights: • Clinical Insight On More Than 400 Marketed Orphan Drugs • Clinical Insight On More Than 1300 Orphan Drugs in Clinical Trials • Orphan Designated Drug Clinical Status by Indication & Country • Global Market Opportunity More Than USD 350 Billion • Market Exclusivity & Patent Protection Criteria for Orphan Drugs • Global & Regional Orphan Drug Market Sales Opportunity • Orphan Drug Reimbursement Policy • Orphan Clinical Pipeline Overview
Global CD233 Antibody Market Clinical Trials Intelligence 2028
Global CD233 Inhibitors Trials Intelligence Report Highlights: • Global CD233 Inhibitors Market Dynamics • Clinical Approaches to Target CD233 Inhibitors • Role of CD233 Inhibitors in Cancer, Autoimmune Disorders • Number of CD233 Inhibitors Drug In Trials • CD233 Inhibitors Approved Patent Insight • CD233 Inhibitors Trials By Phase, Company, Country, Indication • Company Agreement/Partnership/Deals For Ongoing Trials • Global CD233 Inhibitor Market Future Outlook For Report Sample Contact neeraj@kuickresearch.com The successful application of the anti-CTLA-4 and anti-PD-1/PD-L1
Global Gene Therapy Market Clinical Trials Research Insight 2028
Global Gene Therapy Market & Clinical Trials Intelligence Report Highlights • Global Market Gene Therapy Landscape USD 24 Billion Opportunity • Comprehensive Commercial & Clinical insight on 16 Approved Gene Therapies • Gene Therapy Products Dosage & Price Analysis • Comprehensive Clinical Insight On 1700 Gene Therapies In Clinical Trials • Information On 45 Orphan Designated Gene Therapies By Indication, Country, Company • Global Gene Therapy Clinical Trials Insight By Phase, Country, Formulations, Company, Indication, Target •
TROP2 Targeted Therapy Trodelvy Market Clinical Trials Insight 2026
Global TROP2 Antibody Market & Clinical Trials Insight 2026 Report Analysis and Data Highlights: • Research Methodology • Global & Regional Market Analysis • Global TROP2 Antibody Market Opportunity Assessment: > USD 4 Billion • Market and Drug Sales Insight 2020 Till 2026 • Approved Drug In Market: 1 Drugs • Approved TROP2 Antibody Patent, Price and Sales insight 2020 Till 2026 • Future Market Assessment By Indication Till 2026 • Ongoing Clinical Trials Assessment by Status, Phase & Region • Key Market Dynamics • Competitor Landscape Download Report:

All 5 Releases


More Releases for Rheumatoid

How To Cure Rheumatoid Arthritis 2021 ?
Grocare® launches new kit to manage Rheumatoid Arthritis - New findings support research-based kit for management of Rheumatoid Arthritis Pune, May 13, 2021: Pune-based Grocare® has recently launched an advanced research-based kit that alleviates and controls Rheumatoid Arthritis, conditions. This kit contains Absogen®, GC® and Acidim® designed to correct mitochondrial imbalance, build immunity and balance PH, respectively. Grocare® is a pharmaceutical company that has conducted extensive research on Rheumatoid Arthritis. The company’s data
Global Rheumatoid Arthritis Drugs Market | MarketResearchReports.biz
Latest industry research report on: Global Rheumatoid Arthritis Drugs Market | Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts The Rheumatoid Arthritis Drugs Market has been comprehensively detailed in the report with special focus on a range of key elements such as market share, forecast and base figures, CAGR, driving factors, growth restraints, and business opportunities. Buyers of the report are expected to be informed about significant
Rheumatoid Arthritis Treatment Market
Rheumatoid arthritis (RA) is the most common autoimmune arthritis affecting more than 1.3 million U.S. citizens (American College of Rheumatology). More surprising is to know that around 75% of this affected population is women. Affecting the joints at any age, rheumatoid arthritis needs to be addressed early to avoid expensive joint replacement surgery. While it can affect any joint, small joints in hand and feet tend to be affected the
Global Rheumatoid Arthritis Drug Market Outlook 2022
“Global Rheumatoid Arthritis Drug Market Outlook 2022” report gives comprehensive clinical and non-clinical insight on various trends associated with the rheumatoid arthritis drug market across the developed and developing market. Report helps to identify the basic classification and molecular mechanism of action of rheumatoid arthritis drugs available in the market. The top 5 leading DMARDs (Humira, Enbrel, Remicade, Simponi and Otezla) have dominated the overall anti-rheumatics market with
Rheumatoid Arthritis Treatment Market
Rheumatoid arthritis (RA) is the most common autoimmune arthritis affecting more than 1.3 million U.S. citizens (American College of Rheumatology). More surprising is to know that around 75% of this affected population is women. Affecting the joints at any age, rheumatoid arthritis needs to be addressed early to avoid expensive joint replacement surgery. While it can affect any joint, small joints in hand and feet tend to be affected the
Global Rheumatoid Arthritis Market Report: 2016 Edition
Arthritis means inflammation in a joint. Inflammation is a normal immune response in a body. It happens when the body, no longer has the ability to turn off the inflammatory response and thereby start damaging the healthy tissues of the body. This inflammation causes redness, warmth, swelling, and pain within the joint. There are more than 100 different types of arthritis, with different causes and treatment methods. Major classification of